Trial Profile
An Open Label Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BAY 1841788 in Japanese Subjects With Metastatic Castration-resistant Prostate Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Aug 2022
Price :
$35
*
At a glance
- Drugs Darolutamide (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Bayer; Bayer Yakuhin
- 04 Jul 2022 Results of pooled analysis from NCT02363855, NCT01317641/NCT01429064, and NCT01784757, evaluating safety and tolerability of long-term treatment with darolutamide in patients, presented at the 37th Congress of the European Association of Urology
- 19 Feb 2022 Results of pooled analysis assessing long term safety by using data from three phase I/II studies presented at the 2022 Genitourinary Cancers Symposium
- 24 Jan 2018 Status changed from active, no longer recruiting to completed.